Phagenesis · 1 week ago
Therapy Development Manager
Phagenesis is seeking a Therapy Development Manager responsible for developing and managing sales strategy as well as commercialization processes. The role involves executing revenue plans, managing product pricing, and ensuring compliance with regulatory requirements.
Responsibilities
Execution of the Company revenue plan and achievement of agreed business KPIs
Establishing and managing pricing of the Company’s products
Responsible for all regulatory and institutional requirements for product introduction
Work closely with Marketing to develop value proposition messaging based on clinical data and segment strategy
Represent Phagenesis at local or national US congresses in alignment with Marketing
Providing feedback and direction to QA group based on clinical experience
Qualification
Required
Possess a Degree in science/nursing/business and/or Pharma certificate
At least 5 years sales experience in a sales driven environment in the medical devices / Pharma industry with demonstrated success, including sales operations within integrated health systems, purchasing groups and the VA organization
Possess a positive attitude with willingness to learn
Excellent interpersonal skills and proficiency in English (spoken and written)
Working beyond normal working hours and weekends will be required from time to time
Entrepreneurial attitude
Possess a valid driver´s license
Preferred
Experience of stroke, neurology, ICU or dysphagia markets
Training others in use of medical devices
Experience of selling new products into new markets
Experience in selling capital equipment
Demonstrated success selling into complex medical/clinical settings
Forecasting and business planning, including establishment of budgets
Company
Phagenesis
Phagenesis is engaged in the development of a device to treat dysphagia, a condition that disables the safe swallowing of food.
Funding
Current Stage
Late StageTotal Funding
$71.4MKey Investors
MedTech InnovatorInventages Venture Capital Investment Inc.
2024-03-04Series D· $42M
2022-06-07Non Equity Assistance
2016-09-02Acquired
Recent News
2025-05-04
2025-04-02
Company data provided by crunchbase